Endometrial cancer (EC) has four molecular subtypes with strong prognostic value and
therapeutic implications. The most common subtype (NSMP; No Specific Molecular Profile) …

Purpose: The clinical significance of the p53-abnormal (p53abn) molecular subtype in stage
I low-grade endometrioid endometrial carcinoma (EEC) is debated. We aimed to review …

Aims The significance of subclonal expression of p53 (abrupt transition from wild‐type to
mutant‐pattern staining) is not well understood, and the arbitrary diagnostic cut‐off of 10 …

Methods Forty-one carcinosarcomas were identified from a cohort of 973 endometrial
carcinomas diagnosed in 2016. We assessed immunostaining and sequencing data and …

Objective The presence of the microcystic elongated and fragmented (MELF) pattern,
distinguished by its microcystic, elongated and fragmented attributes, constitutes a common …

Objectives Despite recommendations for integrating molecular classification of endometrial
cancers (EC) into pathology reporting and clinical management, uptake is inconsistent. To …

Abstract Background In 2013, The Cancer Genome Atlas Research Network suggested that
endometrial carcinoma patients may be reclassified into four molecular prognostic groups …

Background Endometrial carcinoma (EC) is the sixth most common cancer in women. P53
gene expression in patients with endometrial cancer can predict the efficacy and prognosis …

Purpose: Shallow whole-genome sequencing (sWGS) can detect copy-number (CN)
aberrations. In high-grade serous ovarian cancer (HGSOC) sWGS identified CN signatures …

The clinical heterogeneity of early-stage endometrial cancer (EC) is worthy of further study to
identify high-quality prognostic markers and their potential role in aggressive tumor …